Adam B Keeton

List of Publications by Citations

25 papers	606 citations	12 h-index	24 g-index
25 ext. papers	795 ext. citations	4.7 avg, IF	3.25 L-index

#	Paper	IF	Citations
25	Sulindac selectively inhibits colon tumor cell growth by activating the cGMP/PKG pathway to suppress Wnt/β-catenin signaling. *Molecular Cancer Therapeutics*, **2013**, 12, 1848-59	6.1	83
24	Sulindac sulfide selectively inhibits growth and induces apoptosis of human breast tumor cells by phosphodiesterase 5 inhibition, elevation of cyclic GMP, and activation of protein kinase G. *Molecular Cancer Therapeutics*, **2009**, 8, 3331-40	6.1	82
23	Inhibition of PDE5 by sulindac sulfide selectively induces apoptosis and attenuates oncogenic Wnt/β-catenin-mediated transcription in human breast tumor cells. *Cancer Prevention Research*, **2011**, 4, 1275-84	3.2	77
22	A novel sulindac derivative that does not inhibit cyclooxygenases but potently inhibits colon tumor cell growth and induces apoptosis with antitumor activity. *Cancer Prevention Research*, **2009**, 2, 572-80	3.2	68
21	Colon tumor cell growth-inhibitory activity of sulindac sulfide and other nonsteroidal anti-inflammatory drugs is associated with phosphodiesterase 5 inhibition. *Cancer Prevention Research*, **2010**, 3, 1303-13	3.2	62
20	A novel sulindac derivative that potently suppresses colon tumor cell growth by inhibiting cGMP phosphodiesterase and β-catenin transcriptional activity. *Cancer Prevention Research*, **2012**, 5, 822-33	3.2	56
19	β-catenin nuclear translocation in colorectal cancer cells is suppressed by PDE10A inhibition, cGMP elevation, and activation of PKG. *Oncotarget*, **2016**, 7, 5353-65	3.3	28
18	Suppression of β-catenin/TCF transcriptional activity and colon tumor cell growth by dual inhibition of PDE5 and 10. *Oncotarget*, **2015**, 6, 27403-15	3.3	27
17	Synthesis and biological evaluation of certain hydrazonoindolin-2-one derivatives as new potent anti-proliferative agents. *Journal of Enzyme Inhibition and Medicinal Chemistry*, **2018**, 33, 867-878	5.6	24
16	New hydrazonoindolin-2-ones: Synthesis, exploration of the possible anti-proliferative mechanism of action and encapsulation into PLGA microspheres. *PLoS ONE*, **2017**, 12, e0181241	3.7	23
15	Phosphodiesterase 10A is overexpressed in lung tumor cells and inhibitors selectively suppress growth by blocking β-catenin and MAPK signaling. *Oncotarget*, **2017**, 8, 69264-69280	3.3	16
14	Exploiting RAS Nucleotide Cycling as a Strategy for Drugging RAS-Driven Cancers. *International Journal of Molecular Sciences*, **2019**, 21,	6.3	12
13	Extending the use of tadalafil scaffold: Development of novel selective phosphodiesterase 5 inhibitors and histone deacetylase inhibitors. *Bioorganic Chemistry*, **2020**, 98, 103742	5.1	9
12	PDE5 and PDE10 inhibition activates cGMP/PKG signaling to block Wnt/β-catenin transcription, cancer cell growth, and tumor immunity. *Drug Discovery Today*, **2020**, 25, 1521-1527	8.8	7
11	The path to the clinic: a comprehensive review on direct KRAS inhibitors.. *Journal of Experimental and Clinical Cancer Research*, **2022**, 41, 27	12.8	7
10	New Isatin-Indole Conjugates: Synthesis, Characterization, and a Plausible Mechanism of Their in vitro Antiproliferative Activity. *Drug Design, Development and Therapy*, **2020**, 14, 483-495	4.4	7
9	Enhancing anticancer activity of checkpoint immunotherapy by targeting RAS. *MedComm*, **2020**, 1, 121-128	2.8	6

8	Discovery of trisubstituted pyrazolines as a novel scaffold for the development of selective phosphodiesterase 5 inhibitors. *Bioorganic Chemistry*, **2020**, 104, 104322	5.1	3
7	Abstract 2707: A novel RAS inhibitor, MCI-062, inhibits colon tumor growth in vivo and activates antitumor immunity **2019**,		3
6	Antiproliferative activity and possible mechanism of action of certain 5-methoxyindole tethered C-5 functionalized isatins. *Drug Design, Development and Therapy*, **2019**, 13, 3069-3078	4.4	2
5	Suppression of Colon Tumorigenesis in Mutant Mice by a Novel PDE10 Inhibitor that Reduces Oncogenic Catenin. *Cancer Prevention Research*, **2021**, 14, 995-1008	3.2	2
4	Targeting cGMP/PKG signaling for the treatment or prevention of colorectal cancer with novel sulindac derivatives lacking cyclooxygenase inhibitory activity **2020**, 3, 1-6		1
3	From Celecoxib to a Novel Class of Phosphodiesterase 5 Inhibitors: Trisubstituted Pyrazolines as Novel Phosphodiesterase 5 Inhibitors with Extremely High Potency and Phosphodiesterase Isozyme Selectivity. *Journal of Medicinal Chemistry*, **2021**, 64, 4462-4477	8.3	1
2	Pan-RAS inhibitors: Hitting multiple RAS isozymes with one stone.. *Advances in Cancer Research*, **2022**, 153, 131-168	5.9	0
1	Novel thiazolidine derivatives as potent selective pro-apoptotic agents. *Bioorganic Chemistry*, **2021**, 114, 105143	5.1	0